Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term ci [Chemically Induced]. Found 3 abstracts

Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, Staroslawska E, Sosman J, McDermott D, Bodrogi I, Kovacevic Z, Lesovoy V, Schmidt-Wolf IG, Barbarash O, Gokmen E, O'Toole T, Lustgarten S, Moore L, Motzer RJ, Global AT. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. New England Journal of Medicine. 2007 May 31;356(22):2271-81.
Badawi AF, Eldeen MB, Liu Y, Ross EA, Badr MZ. Inhibition of rat mammary gland carcinogenesis by simultaneous targeting of cyclooxygenase-2 and peroxisome proliferator-activated receptor gamma. Cancer Research. 2004 Feb;64(3):1181-9.
Rogers BB. Taxol: a promising new drug of the '90s. Oncology Nursing Forum. 1993 Nov;20(10):1483-9.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term ci [Chemically Induced]

ci [Chemically Induced] Antineoplastic Agents Female aa [Analogs & Derivatives] ae [Adverse Effects] de [Drug Effects] EC 1-14-99-1 (cyclooxygenase 2) 0 (Protein Kinase Inhibitors) 0 (Antineoplastic Agents) Leucine Clinical Trials ph [Physiology] Transcription Factors 61-90-5 (Leucine) Heart Prostaglandin-Endoperoxide Synthase tu [Therapeutic Use] Carcinogens pc [Prevention & Control] 35661-60-0 (N-(fluorenyl-9-methoxycarbonyl)leucine) Experimental Mammary Neoplasms Antineoplastic Combined Chemotherapy Protocols 0 (Sulfonamides) 41598-07-6 (Prostaglandin D2) Cytoplasmic and Nuclear Receptors tu [Therapeutic Use] Proportional Hazards Models 0 (Fluorenes) ai [Antagonists & Inhibitors] Leukopenia sc [Secondary] 0 (cci 779) Methylnitrosourea bi [Biosynthesis] Dinoprostone Cell Cycle 0 (15-deoxyprostaglandin J2) 53123-88-9 (Sirolimus) Anticarcinogenic Agents en [Enzymology] Nervous System 0 (Anticarcinogenic Agents) Hematologic Diseases Cytoplasmic and Nuclear) 0 (Receptors 0 (Carcinogens) pa [Pathology] Sprague-Dawley Rats ag [Agonists] Fluorenes Oncologic Nursing EC 2-7-1-37 (Protein Kinases) Interferon-alpha Adult 169590-42-5 (celecoxib) mo [Mortality] 363-24-6 (Dinoprostone) dt [Drug Therapy] ad [Administration and Dosage] 0 (Cyclooxygenase Inhibitors) Survival Analysis Isoenzymes Sirolimus Drug Synergism Middle Aged Prostaglandin D2 Drug Incompatibility Male 0 (Isoenzymes) Cell Division EC 2-7-1 (mTOR protein) Renal Cell Carcinoma Sulfonamides 0 (Transcription Factors) me [Metabolism] Kidney Neoplasms Protein Kinases ad [Administration & Dosage] Prognosis 0 (Interferon-alpha) EC 1-14-99-1 (Prostaglandin-Endoperoxide Synthase) Apoptosis pd [Pharmacology] 684-93-5 (Methylnitrosourea) Protein Kinase Inhibitors Rats Gastrointestinal System 80 and over Aged Cyclooxygenase Inhibitors Aged
Last updated on Wednesday, February 05, 2020